ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    sanifit
Previous Study | Return to List | Next Study

Effect of SNF472 on Progression of Cardiovascular Calicification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02966028
Recruitment Status : Active, not recruiting
First Posted : November 17, 2016
Last Update Posted : August 22, 2018
Sponsor:
Collaborator:
Clinipace Worldwide
Information provided by (Responsible Party):
Laboratoris Sanifit

Brief Summary:
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12‑month (52 weeks) period in ESRD patients on HD

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Cardiovascular Abnormalities Calcifications, Vascular Endstage Renal Disease ESRD Coronary Artery Calcification Drug: SNF472 Drug: Placebo Phase 2

Detailed Description:
Reducing the progression of cardiovascular calcification (CVC) in HD patients may improve the severe burden of CV disease related to the underlying ESRD. As no therapy is currently indicated to target CVC, there is a need to investigate the ability of SNF472 to reduce CVC progression and, ultimately, to improve CV outcomes in HD patients. This phase 2b double-blind, randomised, placebo-controlled study is designed to assess the effect of SNF472 on the progression of CVC as measured by calcium volume and CAC/Agatston scores in ESRD patients receiving HD. The study hypothesis is that administration of SNF472 over 52 weeks can slow the progression of CVC in this patient population compared to placebo.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD)
Study Start Date : November 2016
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Failure

Arm Intervention/treatment
Experimental: SNF472 300 mg
Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
Drug: SNF472
Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.

Experimental: SNF 472 600 mg
Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
Drug: SNF472
Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.

Placebo Comparator: Matching Placebo
Placebo arm: 2 vials of physiological saline
Drug: Placebo
Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.




Primary Outcome Measures :
  1. Absolute change in coronary artery calcium volume scores [ Time Frame: Baseline (Week 1, Day 1) and Week 52 ]
    Measured by CT scan



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female or male patients, 18 to 80 years (inclusive) of age at randomisation
  • CAC score of 100 to 3500 AU (Agatston Units) inclusive within a 3-week period prior to randomisation as measured by a multi-detector CT scanner
  • Patients who are EITHER ≥ 55 years OR have a history of diabetes mellitus at randomisation
  • Patients on HD for ≥ 6 months prior to randomisation
  • Willing and able to understand and sign the informed consent

Exclusion Criteria:

  • Scheduled date for kidney transplant from a known living donor
  • Weight above 300 lbs (136 kg)
  • Hospitalisation in the previous 3 months prior to randomisation for unstable angina, MI, stroke, transient ischaemic attack, amputation or peripheral or coronary bypass surgery
  • History of unstable heart failure in the previous 3 months, defined as an unplanned presentation to a hospital or dialysis treatment facility with signs/symptoms of acute pulmonary edema and requiring ultrafiltration therapy
  • History of cancer that has been in remission for < 5 years prior to randomisation. A history of basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin is allowed
  • Pregnant or trying to become pregnant, currently breast-feeding, or of child-bearing potential (including peri-menopausal women who have had a menstrual period within one year) and not willing to practice birth control using a double barrier method (criteria apply to women only) at least 30 days post last dose of study medication
  • Hypocalcaemia defined as a serum calcium below 8.0 mg/dL (or 2.0 mmol/L) for the serum calcium most proximal to screening per patient's medical records
  • Extreme elevation in serum phosphorous, defined as a serum phosphorous above 10 mg/dL (or 3.23 mmol/L) within the last 2 months proximal to screening per patient's medical records
  • Uncontrolled hypertension defined as any 2 or more consecutive post-dialysis diastolic blood pressure (DBP) > 100 mmHg within the last 2 months proximal to screening expected survival < 2 years in the Investigator's medical opinion
  • Known active drug or alcohol abuse within 1 year of randomisation
  • Use of other investigational drugs within 30 days of randomisation
  • Non-compliance with dialysis treatment which, in the opinion of the Investigator, evidenced by either repeated missed dialysis treatments or significant non-compliance with the patient's medication regimen
  • Inability to comply with all required study procedures and schedule, inability to speak and read in the protocol-derived language of that patient's clinical site, or unwillingness or inability to give written informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02966028


  Show 75 Study Locations
Sponsors and Collaborators
Laboratoris Sanifit
Clinipace Worldwide
Investigators
Study Director: Alex Gold, MD Sanifit Chief Medical Officer

Responsible Party: Laboratoris Sanifit
ClinicalTrials.gov Identifier: NCT02966028     History of Changes
Other Study ID Numbers: SNFCT2015-05
First Posted: November 17, 2016    Key Record Dates
Last Update Posted: August 22, 2018
Last Verified: August 2018

Keywords provided by Laboratoris Sanifit:
CAC
calcium
ESRD
calcification
cardiovascular
heart
kidney
hemodialysis
Agatston

Additional relevant MeSH terms:
Cardiovascular Diseases
Kidney Diseases
Kidney Failure, Chronic
Calcinosis
Coronary Artery Disease
Cardiovascular Abnormalities
Vascular Calcification
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Calcium Metabolism Disorders
Metabolic Diseases
Coronary Disease
Myocardial Ischemia
Heart Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Congenital Abnormalities